Cullinan Therapeutics, Zipalertinib, CLN-081, TAS6417, EGFR, EGFR Exon 20 Insertion, EGFR Exon20ins, NSCLC, Non-Small Cell Lung Cancer,

CAMBRIDGE, Mass. — October 1, 2026 Cullinan Therapeutics, Inc. announced the initiation of a New Drug Application (NDA) submission...